Presented by
Management Forum

The end of the Brexit Transition Period – Impact on Pharmaceutical Industry

The very latest information and operational experiences to be shared. 90 minute live webinar 14:00 (UK/London Time Zone)

Find out more

  • Format: Bespoke training
  • CPD: 6 hours for your records (depending on your requirements)
  • Certificate of completion

The end of the transition period - are you prepared for the changes?

The UK has left the EU, and the transition period has now ended. This will have major implications for all aspects of Medicines Regulations in the UK.

During this 90 minute webinar, our expert speaker Dr David Jefferys will talk about the implications and the new opportunities that will arise, including:

  • New International Collaborations
  • The future requirements for Orphan applications and Paediatrics
  • Batch Release and Compliance testing
  • New Safety and PV arrangements
  • Clinical Trial Controls in the UK
  • The implications of the Northern Ireland Protocol
  • The future arrangements for variations
  • The conversion of current EU Centralised Authorisations into UK Licenses
  • The new authorisation routes
  • The legislative changes

The webinar will include a 45 minute presentation, followed by a discussion and Q&A session.

The The end of the Brexit Transition Period – Impact on Pharmaceutical Industry course will cover:

The end of the Brexit Transition Period – Impact on Pharmaceutical Industry

  • Introduction
  • New International Collaborations
  • The future requirements for Orphan applications and Paediatrics
  • Batch Release and Compliance testing
  • New Safety and PV arrangements
  • Clinical Trial Controls in the UK
  • The implications of the Northern Ireland Protocol
  • The future arrangements for variations
  • The conversion of current EU Centralised Authorisations into UK Licenses
  • The new authorisation routes
  • The legislative changes
  • Q&A and discussion session


David Jefferys

Dr David Jefferys is Senior Vice President for Global Regulatory, Government Relations, Public Affairs and Patient Safety (EMEA, Russia and Australasia) at Eisai. After qualifying, he worked in clinical and academic medicine before spending 20 years as a senior regulator for both medicines and medical devices.

He was executive director of the UK Medicines Control Agency, CEO and Director of the MDA and joint CEO of the MHRA. He was involved in the establishment of the European Medicines Agency, is a CPMP/CHMP member and Chair of the MRFG and PER scheme. For the last ten years he has worked in industry and chairs several key committees for ABPI,EFPIA and IFPMA.

More details

We don't have any currently scheduled dates for this course but we can customise it to your requirements and deliver it on an in-house basis for any number of your staff or colleagues.

See below or contact us to discuss yor requirements.

Reviews of IPI's The end of the Brexit Transition Period – Impact on Pharmaceutical Industry training course


Excellent, glad I attended.

Jan 27 2021

Wendy Richings Barrow
Director, Subiaco Associates Ltd

Jan 27 2021

Great - really useful and really enjoyed it. David is a wonderful presenter - a great deal of knowledge.

Lynn Stillman
Principal Consultant, NDA Regulatory Science Ltd.

Jan 27 2021

[Speaker was] knowledgeable and engaging with the audience.

Rosa Chinchilla
Senior Consultant, NDA Regulatory Science

Jan 27 2021

Speakers were knowledgeable and engaging with the audience.

Rosa Chinchilla
Senior Consultant, NDA Regulatory Science

Mar 2 2021

Very good overall.

Ilaria Grisoni
Senior Director, Head of EU/International PV Office & EEA QPPV, Gentium S.r.l. (Jazz Pharmaceuticals Company)

Jan 27 2021

[Speaker was] very Knowledgeable.

Ian Lafferty
Technical Director , Upperton Pharma Solutions

Jan 27 2021

Useful summary slides. Interesting Q & A session, indicating many common issues.

Norah Lightowler
Partner, Lightowler Associates

Jan 27 2021

Well informed. Clear presentation. Answered questions honestly, in view of the evolving legislation. Useful summary slides. Interesting Q & A session, indicating many common issues.

Norah Lightowler
Partner, Lightowler Associates

Mar 2 2021

Really helpful and reassuring to know that I have understood the situation thus far. Also helped to identify areas where I can look for more information.

Shirley-Ann van der Spuy
Managing Director & EU QPPV, Red Line Pharmacovigilance Ltd

Nov 30 2020

A well put together webinar containing key information - even on the morning of the webinar, providing breaking news on legislation updates!

Chris Dodd
Medical Regulatory Manager, Mexichem UK Ltd

UK

  • Almac Group Limited
  • B&B QP Serviced Ltd
  • BMS
  • Bristol-Myers Squibb
  • Bristows LLP
  • Callisto Consulting Ltd
  • Callisto Regulatory Consulting Ltd
  • CMS Cameron McKenna Nabarro Olswang LLP
  • Cycle Pharmaceuticals Ltd.
  • Gilead Sciences
  • Jazz Pharma
  • Jenson R+ Ltd
  • JensonR+ Ltd
  • LGC
  • Lightowler Associates
  • Limbco Ltd
  • Mexichem UK Ltd
  • NDA Regulatory Science
  • NDA Regulatory Science Ltd.
  • PCI Pharma Services
  • PharmOut Ltd
  • Red Line Pharmacovigilance Ltd
  • Rosemont Pharmaceuticals Ltd
  • SAVIOURS PHARMA CONSULTANCY LTD
  • Servier Laboratories Ltd
  • Subiaco Associates Ltd
  • Torbay Pharmaceuticals Torbay and South Devon NHS Foundation Trust
  • Upperton Pharma Solutions
  • Walgreens Boots Alliance

Spain

  • Faes Farma S.A.
  • FAES Farma SA
  • Qualicaps Europe
  • Veeva Systems

Germany

  • Bela-Pharm GmbH & Co. KG
  • CHEPLAPHARM Arzneimittel GmbH
  • PHOENIX Pharmahandel GmbH & Co KG

Italy

  • Gentium S.r.l. (Jazz Pharmaceuticals Company)
  • Menarini Ricerche Spa
  • Via Monte Rosa 10

Switzerland

  • DEBIOPHARM RESEARCH & MANUFACTURING S.A.
  • Pharma International
  • Swedish Orphan Biovitrum AG

Canada

  • Aurinia Pharmaceuticals Inc.

Cyprus

  • Delorbis Ltd

Finland

  • Vetcare Oy

Ireland

  • NorthStar Healthcare

Netherlands

  • Spektrum Clinical Consultancy

Multiple colleagues?
Talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra BEER
Training expert

+44 (0)20 7749 4749

inhouse@ipi.academy